In 2016, the difference between the amount that the Medicare drug benefit program reported spending on 29 brand-name combination medications and the estimated spending for generic constituents for the same number of doses was $925 million, according to a study released today by JAMA. This includes $235 million if generic products had been prescribed at the same doses, $219 million using generic substitution at different doses, and $471 million from substitution of similar generic medications in the same therapeutic class. “Promoting generic substitution and therapeutic interchange through prescriber education and more rational substitution policies may offer important opportunities to achieve substantial savings in the Medicare drug benefit program,” the authors wrote.
 

Related News Articles

Headline
The Centers for Medicare…
Headline
Senate Finance Committee Ranking Member Ron Wyden, D-Ore., along with several other Democratic senators, yesterday introduced bills aimed at increasing…
Headline
The Department of Health and Human Services’ Center for Medicare and Medicaid Innovation today announced a new payment model for emergency ambulance services…
Headline
Committee Chairman Richard Neal, D-Mass., and Ranking Member Kevin Brady, R-Texas, said they are committed to working on bipartisan reforms to lower drug…
Headline
The AHA today expressed support for the Resident Physician Shortage Reduction Act, legislation that would add 15,000 Medicare-funded residency positions over…
Headline
The Centers for Medicare…